Floatz logo

Cyclophosphamide

T-cell Childhood Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)Small moleculePhase 3Active
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
59/ 100
Competitive Position
95/ 100

Competitive context

17 Active assets in the T-cell Childhood Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
METHOTREXATE
National Cancer Institute (NCI)
Phase 3BBB
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 3BBB
PEGASPARGASE
National Cancer Institute (NCI)
Phase 3BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 3BBB
ETOPOSIDE
National Cancer Institute (NCI)
Phase 3BB

View all 37 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →